< Back to search
Filter
1
Active & ResponsiveNew

A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults

for
Respiratory Syncytial Virus (RSV),
Location: Quebec, Victoriaville
Sponsor: ModernaTX, Inc.

Sex: All

Age: 60+

Code: NCT07764237

Phase1, Recruiting
Active & Responsive

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

for
Respiratory Syncytial Virus (RSV)
Location: Baltimore MD
Sponsor: Johns Hopkins University

Sex: All

Age: 18+

Code: NCT07050732

Phase2, Recruiting
Active & Responsive

Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy

for
RSV,
Location: Halifax, Montreal, Ottawa
Sponsor: Canadian Immunization Research Network

Sex: Female

Age: 18 - 49

Code: NCT07097012

Recruiting

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

for
RSV Infection
Location: New Haven CT
Sponsor: Yale University

Sex: All

Age: 0 - 1

Code: NCT06172660

Recruiting

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

for
RSV Infection
Location: Boston MA, Norfolk VA, Richmond VA,
Sponsor: Pfizer

Sex: All

Age: 0+

Code: NCT06866405

Phase3, Recruiting

Interested in new rsv infection trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

for
Respiratory Syncytial Virus Infections
Location: New Haven CT, Philadelphia PA, Washington D.C. DC,
Sponsor: University of Alabama at Birmingham

Sex: All

Age: 0 - 2

Code: NCT05026749

Phase3, Recruiting

A Study of BLB-201 RSV Vaccine in Infants and Children

for
Respiratory Syncytial Virus Infections
Location: Beachwood OH, Greenville SC, Allen Park MI,
Sponsor: Blue Lake Biotechnology Inc.

Sex: All

Age: 0 - 5

Code: NCT05655182

Phase1, Phase2, Recruiting

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

for
Respiratory Syncytial Virus Infections
Location: Boston MA, Providence RI, The Bronx NY, Richmond VA,
Sponsor: Shionogi

Sex: All

Age: 18+

Code: NCT07214571

Phase2, Recruiting

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

for
Respiratory Syncytial Virus Infections+Metapneumovirus
Location: Lenexa KS, Seattle WA
Sponsor: GlaxoSmithKline

Sex: All

Age: 18 - 70+

Code: NCT07628049

Phase1, Phase2, Recruiting

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

for
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease,
Location: Houston TX, Seattle WA, Duarte CA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT06817889

Phase2, Recruiting
New

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

for
Respiratory Syncytial Virus (RSV)
Location: Los Angeles CA
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07768345

Phase3, Recruiting

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

for
Respiratory Infection Virus, COVID -19, RSV, FLU
Location: San Ysidro CA, La Jolla CA
Sponsor: University of California, San Diego

Sex: All

Age: 0+

Code: NCT07147517

Recruiting

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

for
COVID-19, SARS-CoV-2 Infection, RSV, Influenza
Location: Portland OR
Sponsor: VA Office of Research and Development

Sex: All

Age: 18+

Code: NCT06160128

Recruiting

Infant RSV Immunity Study

for
Respiratory Synctial Virus, Asthma Childhood
Location: Vancouver
Sponsor: University of British Columbia

Sex: All

Age: 0

Code: NCT07653347

Recruiting

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

for
Covid19
Location: Raleigh NC, Lenexa KS
Sponsor: Meissa Vaccines, Inc.

Sex: All

Age: 18 - 69

Code: NCT04798001

Phase1, Recruiting

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

for
Respiratory Syncytial Virus Immunization,
Location: Staten Island NY, Philadelphia PA, Charlottesville VA,
Sponsor: Sanofi

Sex: All

Age: 60+

Code: NCT07734649

Phase1, Phase2, Recruiting